D6M.F GENEDRIVE PLC LS -015
- Market cap
- EUR 19.8M
- P/E
- -
- P/B
- 0.44x
- ROE
- -363.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2025.
Is D6M.F undervalued?
Graham numberThe Graham number of GENEDRIVE PLC LS -015 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENEDRIVE PLC LS -015 fundamental analysis
No fundamental analysis for GENEDRIVE PLC LS -015 yet.
GENEDRIVE PLC LS -015 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENEDRIVE PLC LS -015
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of …
Full company profileGENEDRIVE PLC LS -015 financial statements
GENEDRIVE PLC LS -015 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 49.0K | 55.0K | 332K | 764K |
| Operating Income | -5.62M | -5.22M | -5.31M | -5.38M |
| EBITDA | -5.37M | -5.70M | -7.49M | -5.36M |
| Net Income | -4.68M | -5.15M | -7.08M | -5.23M |
| EPS | -0.04 | -0.04 | -0.01 | -0.01 |
| Balance Sheet | ||||
| Total Assets | 6.62M | 4.51M | 6.80M | 2.82M |
| Total Liabilities | 1.01M | 2.47M | 1.44M | 1.38M |
| Shareholders' Equity | 5.61M | 2.04M | 5.36M | 1.44M |
| Cash & Short-term Investments | 4.59M | 2.60M | 5.19M | 1.18M |
| Cash Flow | ||||
| Operating Cash Flow | -4.59M | -3.81M | -3.77M | -5.14M |
| Capital Expenditure | 62.0K | 52.0K | 29.0K | 23.0K |
| Free Cash Flow | -4.66M | -3.86M | -3.80M | -5.17M |
| Ratios | ||||
| ROE | -83.3% | -252.3% | -132.0% | -363.8% |
| ROA | -70.6% | -114.3% | -104.0% | -185.8% |
| Net Profit Margin | -9,540.8% | -9,363.6% | -2,131.0% | -684.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENEDRIVE PLC LS -015 dividends
GENEDRIVE PLC LS -015 has not paid dividends in the last 5 fiscal years.
Who owns GENEDRIVE PLC LS -015
- Insiders 44.96%
- Institutions 1.24%
- Public & others 53.80%
- Shares outstanding 1.61B
- Free float 634M
GENEDRIVE PLC LS -015 company profile
- Company name
- GENEDRIVE PLC LS -015
- Ticker
- D6M.F
- ISIN
- GB00B1VKB244
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 43
- Fiscal year end
- June
- Address
- The Incubator Building, Manchester, United Kingdom, M13 9XX
- Phone
- 44 16 1989 0245
- Website
- genedriveplc.com
About GENEDRIVE PLC LS -015
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. genedrive plc has a collaboration agreement with Thermo Fisher Scientific Inc. to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.
GENEDRIVE PLC LS -015 management
2- Dr. Gino Miele Ph.D.CEO, Chief Scientific Officer & Executive Director · born 1970
- Mr. Russell John ShawCFO, Secretary & Director · born 1978